// App-Quantinova.ai

2064 : Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG).

Researchers

Presenter

  • Xuling Lin

Principal Investigators

  • Thomas Joseph Kaley

  • Elena Pentsova

  • Lisa Marie DeAngelis

  • Mariza Daras

  • Igor T. Gavrilovic

  • Ingo K. Mellinghoff

  • Andrew McKeown

  • Malbora Manne

  • Jessica Hansen

  • Linda M. Bavisotto

  • Greg Gorman

  • Michael Lamson

  • Rashida A. Karmali

  • Antonio Marcilio Padula Omuro

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Porta Clinica PLLC, Seattle, WA

  • Samford University, Birmingham, AL

  • Nuventa Pharma Sciences, Research Triangle Park, NC

  • Tactical Therapeutics, Inc., Brooklyn, NY

Locations

  • United States

Companies

  • Porta Clinica PLLC

  • Tactical Therapeutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • CAI orotate

  • Temozolomide

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Multicenteric

Phase

  • I

Study Id's

  • NCT01107522

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved